Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

3(50%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

83%

Ph early_phase_1

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Early Phase 1First-in-human

1(16.7%)

Phase 1Safety & dosage

5(83.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Terminated(1)

Detailed Status

Recruiting3

Not yet recruiting1

Withdrawn1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 11 (16.7%)

Phase 15 (83.3%)

Trials by Status

not_yet_recruiting117%

withdrawn117%

recruiting350%

completed117%

Recent Activity

3 active trials

Showing 5 of 6

completedphase_1

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

NCT06946199

recruitingphase_1

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

NCT07215650

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT07236411Phase 1

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Completed

NCT07408869Phase 1

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

Withdrawn

NCT07353450Early Phase 1

A Study of Cizutamig for Patients With Ulcerative Colitis

Not Yet Recruiting

NCT06946199Phase 1

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Recruiting

NCT07215650Phase 1

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Recruiting

NCT07215663Phase 1

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

Recruiting

All 6 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 6